Pharmaceutical Costs

A Glossary of All Terms Pharma

If you’re working to control the cost of prescription drugs, you need to know the lingo used by the pharmaceutical industry. Below is a glossary of terms commonly used by players in the drug research, regulation, manufacturing, distribution, and purchasing worlds. Drug Product Terms Brand product: Branded products are not generic drugs or products. A brand can be […]

Read More
  • While the Administration Mulls How to Curb Prescription Costs, State Legislatures Take the Lead
    State Health Policy Blog

    As the country awaits the Administration’s plan to curb Rx drug costs, states take the lead, proposing and passing legislation to lower costs, despite industry opposition. As we await the details of President Trump’s proposals to curb escalating drug prices, states are continuing to push legislation to lower the cost of prescription drugs, despite the strong […]

    Read More
  • States’ Prescription Drug Transparency Laws Open the Black Box of Drug Pricing
    State Health Policy Blog

    Several states have passed drug price transparency laws that require drug makers to report the reasons behind dramatic price increases. These laws are an important first step to shine a light on why drug prices are rapidly climbing. To address a problem, state health policymakers need to understand it, but transparency laws don’t yet give […]

    Read More
  • Legal Challenges of Rx Drug Laws Passed in 2017 Will Shape States’ Future Cost Containment Legislation
    Publications

    As the number of state bills to rein in prescription drug prices grows beyond 150 nationwide in 2018, the first generation of several state laws passed last year are now before the courts. The pharmaceutical industry has consistently challenged drug cost transparency and price gouging legislation passed in 2017 in federal courts. How well these […]

    Read More
  • An Oregon State Lawmaker Crafts a Winning Strategy for Transparency Legislation

    Last week, Oregon Gov. Kate Brown signed a drug cost transparency bill into law that requires drug makers to report the reasons behind dramatic drug price increases. The bill’s leading advocate and architect, state Rep. Robert Nosse, D-Portland, worked for nearly three years to create a prescription cost containment bill that would win bipartisan support […]

    Read More
  • Can States Regulate Drug Costs without Violating Patent Law? Yes, Here’s Why
    State Health Policy Blog

    When states pass laws that enable them to regulate prescription drug costs or mandate drug pricing transparency, the pharmaceutical industry always fires back with lawsuits claiming the states are violating federal law. In 2017, the industry sued every state that enacted drug cost containment legislation claiming they had violated myriad federal laws, including the Patent […]

    Read More
  • Publications

    This National Academy for State Health Policy white paper, States’ Rights: A Patent Law Analysis of NASHP Rate-Setting Model Act by experts at the University of California Hastings College of the Law, explores why state drug rate-setting legislation and other cost containment approaches do not violate federal patent law and can withstand legal challenges. This […]

    Read More
  • How the Federal Government Can Help States Address Rising Prescription Drug Costs
    State Health Policy Blog

    State Medicaid programs, which face rapidly rising drug costs, have few bargaining chips to use when negotiating lower drug costs, due in part to decades-old federal rules that limit their bargaining power. NASHP, with support of The Commonwealth Fund, recently sat down with state and federal policymakers to identify policy and rule changes that could […]

    Read More
  • Four More States Submit Bills to Import Prescription Drugs from Canada
    State Health Policy Blog

    As states pursue a wide range of legislation to address rising drug costs, four more states have joined Utah and Vermont to introduce bills to import prescription drugs from Canada through a state-run, wholesale operation. This market-based approach to providing more affordable medicines from Canada, where prescription drugs cost on average 30 percent less than […]

    Read More
  • Trending Now: State Legislation that Bans Pharmacy Benefit Managers’ “Gag Clauses”
    State Health Policy Blog

    A growing number of state legislatures across the country are introducing bills to outlaw a “gag clause” that prevents pharmacists from telling consumers when there are cheaper prescription drug alternatives available. Some of the bills also require fuller disclosure about the business relationships between pharmacy benefit managers, health plans, and pharmacies in order to address […]

    Read More